MX2024012431A - Tratamientos del cancer con inhibidores de prmt5 cooperativos con mta - Google Patents
Tratamientos del cancer con inhibidores de prmt5 cooperativos con mtaInfo
- Publication number
- MX2024012431A MX2024012431A MX2024012431A MX2024012431A MX2024012431A MX 2024012431 A MX2024012431 A MX 2024012431A MX 2024012431 A MX2024012431 A MX 2024012431A MX 2024012431 A MX2024012431 A MX 2024012431A MX 2024012431 A MX2024012431 A MX 2024012431A
- Authority
- MX
- Mexico
- Prior art keywords
- mta
- cooperative
- cancer treatments
- prmt5 inhibitors
- prmt5
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263329010P | 2022-04-08 | 2022-04-08 | |
| US202263345736P | 2022-05-25 | 2022-05-25 | |
| PCT/US2023/017805 WO2023196545A1 (en) | 2022-04-08 | 2023-04-07 | Cancer treatments using mta-cooperative prmt5 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024012431A true MX2024012431A (es) | 2024-11-08 |
Family
ID=86328467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024012431A MX2024012431A (es) | 2022-04-08 | 2024-10-07 | Tratamientos del cancer con inhibidores de prmt5 cooperativos con mta |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20250228861A1 (https=) |
| EP (1) | EP4504199A1 (https=) |
| JP (1) | JP2025511399A (https=) |
| KR (1) | KR20240169712A (https=) |
| CN (1) | CN119317435A (https=) |
| AU (1) | AU2023249277A1 (https=) |
| CA (1) | CA3255376A1 (https=) |
| CL (1) | CL2024003040A1 (https=) |
| IL (1) | IL315996A (https=) |
| JO (1) | JOP20240223A1 (https=) |
| MX (1) | MX2024012431A (https=) |
| TW (1) | TW202345844A (https=) |
| WO (1) | WO2023196545A1 (https=) |
| ZA (1) | ZA202407596B (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202440126A (zh) * | 2022-11-30 | 2024-10-16 | 美商安進公司 | 利用ｍｔａ協作的ｐｒｍｔ５抑制劑和ｍａｔ２ａ抑制劑之癌症治療 |
| EP4637774A1 (en) * | 2022-12-21 | 2025-10-29 | Amgen Inc. | Cancer treatments using mta-cooperative prmt5 inhibitors |
| AU2024356380A1 (en) * | 2023-10-06 | 2026-04-02 | Amgen Inc. | Cancer treatments using mta-cooperative prmt5 inhibitors |
| TW202519223A (zh) * | 2023-10-31 | 2025-05-16 | 大陸商康百達（四川）生物醫藥科技有限公司 | 一種吡啶衍生物及其在醫藥上的應用 |
| WO2025098450A1 (zh) * | 2023-11-08 | 2025-05-15 | 北京泰德制药股份有限公司 | Prmt5抑制剂及其制备方法 |
| WO2025113703A1 (zh) * | 2023-12-01 | 2025-06-05 | 上海翰森生物医药科技有限公司 | 四并环类衍生物抑制剂、其制备方法和应用 |
| WO2025157284A1 (zh) * | 2024-01-26 | 2025-07-31 | 上海湃隆生物科技有限公司 | 包含prmt5抑制剂和化疗剂的药物组合物 |
| WO2025157287A1 (zh) * | 2024-01-26 | 2025-07-31 | 上海湃隆生物科技有限公司 | 包含prmt5抑制剂和egfr抑制剂的药物组合物 |
| WO2025176054A1 (zh) * | 2024-02-20 | 2025-08-28 | 华润医药研究院（深圳）有限公司 | 三环杂环类化合物及其制备方法和医药用途 |
| WO2025194059A1 (en) * | 2024-03-15 | 2025-09-18 | Prelude Therapeutics Incorporated | Combination treatment regimens - smarca2 degrader with taxane anticancer agent |
| WO2025207705A1 (en) * | 2024-03-26 | 2025-10-02 | Amgen Inc. | Cancer treatments using mta-cooperative prmt5 inhibitors |
| WO2025213154A1 (en) * | 2024-04-05 | 2025-10-09 | Amgen Inc. | Gastrointestinal cancer treatments using mta-cooperative prmt5 inhibitors |
| WO2025250569A1 (en) * | 2024-05-29 | 2025-12-04 | Amgen Inc. | Cancer treatments using mta-cooperative prmt5 inhibitors and mat2a inhibitors |
| WO2025265110A1 (en) * | 2024-06-21 | 2025-12-26 | Amgen Inc. | Oral pharmaceutical compositions comprising a naphthyridine compound |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3129832A1 (en) * | 2019-02-13 | 2020-08-20 | Les Laboratoires Servier | Combination therapies for use in treating cancer |
| JP7787819B2 (ja) * | 2020-02-12 | 2025-12-17 | アムジェン インコーポレイテッド | 新規ｐｒｍｔ５阻害剤 |
| AU2021400942A1 (en) * | 2020-12-16 | 2023-07-06 | Amgen Inc. | PRMT5 inhibitors |
-
2023
- 2023-04-07 CA CA3255376A patent/CA3255376A1/en active Pending
- 2023-04-07 EP EP23721498.6A patent/EP4504199A1/en active Pending
- 2023-04-07 IL IL315996A patent/IL315996A/en unknown
- 2023-04-07 TW TW112113091A patent/TW202345844A/zh unknown
- 2023-04-07 WO PCT/US2023/017805 patent/WO2023196545A1/en not_active Ceased
- 2023-04-07 AU AU2023249277A patent/AU2023249277A1/en active Pending
- 2023-04-07 KR KR1020247037062A patent/KR20240169712A/ko active Pending
- 2023-04-07 CN CN202380045230.7A patent/CN119317435A/zh active Pending
- 2023-04-07 US US18/853,736 patent/US20250228861A1/en active Pending
- 2023-04-07 JP JP2024559031A patent/JP2025511399A/ja active Pending
-
2024
- 2024-10-06 JO JOJO/P/2024/0223A patent/JOP20240223A1/ar unknown
- 2024-10-07 ZA ZA2024/07596A patent/ZA202407596B/en unknown
- 2024-10-07 MX MX2024012431A patent/MX2024012431A/es unknown
- 2024-10-08 CL CL2024003040A patent/CL2024003040A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4504199A1 (en) | 2025-02-12 |
| AU2023249277A1 (en) | 2024-10-17 |
| TW202345844A (zh) | 2023-12-01 |
| CL2024003040A1 (es) | 2025-02-21 |
| WO2023196545A1 (en) | 2023-10-12 |
| ZA202407596B (en) | 2025-06-25 |
| US20250228861A1 (en) | 2025-07-17 |
| KR20240169712A (ko) | 2024-12-03 |
| JOP20240223A1 (ar) | 2024-10-06 |
| CN119317435A (zh) | 2025-01-14 |
| CA3255376A1 (en) | 2023-10-12 |
| IL315996A (en) | 2024-11-01 |
| JP2025511399A (ja) | 2025-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202407596B (en) | Cancer treatments using mta-cooperative prmt5 inhibitors | |
| ZA202300875B (en) | Kat6 inhibitor methods and combinations for cancer treatment | |
| PH12021551833A1 (en) | Enpp1 inhibitors and methods of modulating immune response | |
| MX2024012131A (es) | Composicion farmaceutica, uso de la misma y metodo para tratar el cancer | |
| MX2025007373A (es) | Tratamientos del cancer con inhibidores de prmt5 cooperativos con mta | |
| ECSP045430A (es) | Terapia de combinación para el tratamiento de cancer | |
| WO2022271810A3 (en) | Bicyclic peptidyl pan-ras inhibitors | |
| MX2024006678A (es) | Inhibidor de cdk4 para el tratamiento del cancer. | |
| MX2024004213A (es) | Combinaciones de inhibidores de kras g12d con inhibidores de pi3ka y métodos de tratamiento relacionados. | |
| ZA202304965B (en) | Combination therapy for treating cancer | |
| MX2024014121A (es) | Metodos y composiciones para el tratamiento del exceso de glucocorticoides | |
| WO2023164455A3 (en) | Compositions and methods to modulate the immune system | |
| WO2023046060A8 (zh) | 治疗kras突变的癌症患者 | |
| MX2025011869A (es) | Terapia de combinacion que comprende un inhibidor de parg y un inhibidor de topoisomerasa para tratar cancer | |
| ZA202210302B (en) | Bioinformatics | |
| MX2022016406A (es) | Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un inhibidor de hif-2 alpha y lenvatinib. | |
| MX2022008532A (es) | Inhibidores de hidrocarburo de arilo (ahr) y usos de estos. | |
| MX2025006279A (es) | Tratamientos contra el cancer mediante un inhibidor de prmt5 y un inhibidor de mat2a | |
| MX2020008881A (es) | Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1. | |
| AU2020327022A8 (en) | Method of treating cancer | |
| MX2025011364A (es) | Metodo de tratamiento de cancer de mama en estadio inicial con ribociclib en combinacion con un inhibidor de la aromatasa | |
| WO2021174195A3 (en) | Use of thyromimetics for the treatment of cancer | |
| MX2022016410A (es) | Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un antagonista del pd-1, inhibidor de hif-2 alpha y lenvatinib o una sal aceptable farmeuticamente de estos. | |
| MX2024012300A (es) | Terapia de combinación de agonista de receptor 5 de muerte (dr5) e inhibidor de cinasa 1 tipo polo (plk1) o inhibidor de cinasa dependiente de ciclina (cdk) | |
| WO2021262562A3 (en) | Methods for treating cancer or von-hippel lindau disease using a combination of a pd-1 antagonist, a hif-2 alpha inhibitor, and lenvatinib or a pharmaceutically acceptable salt thereof |